Editor
 |
| Coronavirus pills! |
Various drugs and vaccines are being investigated around the world to prevent coronavirus. In the meantime, US researchers are reporting good news. They claim that they can resist coronavirus, they have successfully tested in the laboratory with drugs or pills that they take in the mouth.
A group of researchers at Emory University, North Carolina University and Vanderbilt University Medical Center in the United States studied the new drugs. Meanwhile, a US company called Ridgeback Biotherapeutics has obtained a license for the drug. The US Food and Drug Administration (FDA) has also approved drug testing.
In the next few months, 10 patients will be tested with virus-resistant drugs. Miami-based Ridgeback Biotherapeutics in Florida is a privately-owned biotechnology organization dealing with infectious diseases.
Researchers at the Emory Institute for Drug Development say the drug is called 'EIDD-2801'. It mainly blocks the reproduction and transmission of high numbers of SARS-Cove-2 viruses. Research articles have been published in the journal Science Translational Medicine. These pills have been shown to prevent the transmission of coronavirus to human lung cell transcripts in the test tube. In addition, they have studied this drug on rats. In this case, they have been shown to prevent the regeneration of the coronavirus, which is closely related to the rat and to improve lung function.
Researchers say their drug has not yet been tested in humans. But if the effect is similar to that of humans, this will be the first pill to cause a COVID-19 pandemic.
According to Johns Hopkins University in the United States, the number of patients with coronavirus has increased by more than 1.4 million 29 thousand 437 by Wednesday morning. Worldwide, coronavirus has died of 82 thousand 74 people. Of those, 17,127 died in Italy, the highest in any country so far.
Experts say it would be a blessing if you get coronary medicine as an oral pill or pill. Because it would be easier for more people to give drugs than to get injected into the veins.
Earlier, a joint team of researchers from universities found that Gilead Science's experimental remodecavage drug was effective in stopping the transcription of coronaviruses. An antiviral drug from an American biotechnology company called Gilead Science is now used in small numbers for some patients. Its name is Remedecavir, and in science, it is called the nucleotide analog. It is a compound similar to the original compound that DNA is made of. Some of these drugs are currently used to prevent the HIV virus. Remediation was developed to prevent the Ebola virus in Africa. It is a broad-spectrum virus resistant. That means it works to prevent several viruses, such as Nipa, MARS, SARS, Ebola and some other viruses. In January this year, the drug was applied to a Washington state patient.
Remedies are currently under discussion because experts have begun clinical trials against the SARS-Cove-2 virus last March. The results can be known by the end of April.
Researchers claim that EIDD-2801 will prevent the transcription of coronavirus successfully compared to Gilead's drugs.
George Painter, executive director of the Emory Institute for Drug Development and professor of chemistry, said the findings of the study are important considering the current COVID-19 problem.
In 2018, Painter and his lab researchers discovered the activities of EIDD-2801 while searching for influenza drugs. Prior to the Corona pandemic last October, Emory National Institute of Allergy and Infectious Disease received $ 15.9 million in funding. Emory University got the money to test the drug against the flu virus. However, when the coronavirus hit, the painter's research team changed their focus.
EIDD-2801 prevents coronavirus's self-copy activity in a way that is different from Remodecivir. The Remodecivir stops original copywriting process completely. EIDD-2801 damages mutations in the virus's RNA, so that RNA is damaged and cannot damage cells. It is also capable of acting against other RNA viruses. So it will be useful as a multiple anti-virus drug. Some antibiotics, such as EIDD-2801, can work for multiple bacteria.
Wayne Holman, the co-founder of Ridgeback Biotherapeutics, a US-based Miami-based company, said the compound they created could be beneficial for health workers, primarily to prevent prophylaxis or infection. Another possible use is to protect the residents and staff of the nursing home from outbreaks. The broader goal, however, is to make mouth pills, which can be given to the patient twice a day at the beginning of the disease.
Ridgeback Biotherapeutics has applied for a test in the United Kingdom in addition to starting a US test. "We worked three to four years in three to four weeks to prevent the new Corona epidemic," Holman said.
References: Essence News, Scientific American
#healthcare #health coverage